Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz Ö, Fischler B, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Özen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P.
Thompson RJ, et al.
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):830-842. doi: 10.1016/S2468-1253(22)00093-0. Epub 2022 Jul 1.
Lancet Gastroenterol Hepatol. 2022.
PMID: 35780807
Free article.
Clinical Trial.
FINDINGS: Between June 21, 2018, and Feb 10, 2020, 62 patients (median age 3.2 [range 0.5-15.9] years) were randomly allocated to placebo (n=20), odevixibat 40 mug/kg per day (n=23), or odevixibat 120 mug/kg per day (n=19). ...
FINDINGS: Between June 21, 2018, and Feb 10, 2020, 62 patients (median age 3.2 [range 0.5-15.9] years) were randomly allocated to placebo ( …